234 related articles for article (PubMed ID: 36455613)
1. Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia.
Uckelmann HJ; Haarer EL; Takeda R; Wong EM; Hatton C; Marinaccio C; Perner F; Rajput M; Antonissen NJC; Wen Y; Yang L; Brunetti L; Chen CW; Armstrong SA
Cancer Discov; 2023 Mar; 13(3):746-765. PubMed ID: 36455613
[TBL] [Abstract][Full Text] [Related]
2. Mutant NPM1 Hijacks Transcriptional Hubs to Maintain Pathogenic Gene Programs in Acute Myeloid Leukemia.
Wang XQD; Fan D; Han Q; Liu Y; Miao H; Wang X; Li Q; Chen D; Gore H; Himadewi P; Pfeifer GP; Cierpicki T; Grembecka J; Su J; Chong S; Wan L; Zhang X
Cancer Discov; 2023 Mar; 13(3):724-745. PubMed ID: 36455589
[TBL] [Abstract][Full Text] [Related]
3. HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia.
Zhu G; Luo H; Feng Y; Guryanova OA; Xu J; Chen S; Lai Q; Sharma A; Xu B; Zhao Z; Feng R; Ni H; Claxton D; Guo Y; Mesa RA; Qiu Y; Yang FC; Li W; Nimer SD; Huang S; Xu M
Nat Commun; 2021 Mar; 12(1):1956. PubMed ID: 33782403
[TBL] [Abstract][Full Text] [Related]
4. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
Juul-Dam KL; Shukla NN; Cooper TM; Cuglievan B; Heidenreich O; Kolb EA; Rasouli M; Hasle H; Zwaan CM
Eur J Med Genet; 2023 Dec; 66(12):104869. PubMed ID: 38174649
[TBL] [Abstract][Full Text] [Related]
6. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
Kühn MW; Song E; Feng Z; Sinha A; Chen CW; Deshpande AJ; Cusan M; Farnoud N; Mupo A; Grove C; Koche R; Bradner JE; de Stanchina E; Vassiliou GS; Hoshii T; Armstrong SA
Cancer Discov; 2016 Oct; 6(10):1166-1181. PubMed ID: 27535106
[TBL] [Abstract][Full Text] [Related]
7. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Fiskus W; Boettcher S; Daver N; Mill CP; Sasaki K; Birdwell CE; Davis JA; Takahashi K; Kadia TM; DiNardo CD; Jin Q; Qi Y; Su X; McGeehan GM; Khoury JD; Ebert BL; Bhalla KN
Blood Cancer J; 2022 Jan; 12(1):5. PubMed ID: 35017466
[TBL] [Abstract][Full Text] [Related]
8. EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML.
Skayneh H; Jishi B; Hleihel R; Hamie M; El Hajj R; Deleuze-Masquefa C; Bonnet PA; El Sabban M; El Hajj H
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408798
[TBL] [Abstract][Full Text] [Related]
9. Mutant NPM1 Maintains the Leukemic State through HOX Expression.
Brunetti L; Gundry MC; Sorcini D; Guzman AG; Huang YH; Ramabadran R; Gionfriddo I; Mezzasoma F; Milano F; Nabet B; Buckley DL; Kornblau SM; Lin CY; Sportoletti P; Martelli MP; Falini B; Goodell MA
Cancer Cell; 2018 Sep; 34(3):499-512.e9. PubMed ID: 30205049
[TBL] [Abstract][Full Text] [Related]
10. Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor.
Nemeckova S; Alexova-Zurkova K; Hainz P; Krystofova J; Mackova J; Roubalova K; Stastna-Markova M; Vrana M; Vydra J
Curr Oncol; 2022 Apr; 29(5):2928-2934. PubMed ID: 35621629
[TBL] [Abstract][Full Text] [Related]
11. Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy.
Wu HC; Rérolle D; Berthier C; Hleihel R; Sakamoto T; Quentin S; Benhenda S; Morganti C; Wu C; Conte L; Rimsky S; Sebert M; Clappier E; Souquere S; Gachet S; Soulier J; Durand S; Trowbridge JJ; Bénit P; Rustin P; El Hajj H; Raffoux E; Ades L; Itzykson R; Dombret H; Fenaux P; Espeli O; Kroemer G; Brunetti L; Mak TW; Lallemand-Breitenbach V; Bazarbachi A; Falini B; Ito K; Martelli MP; de Thé H
Cancer Discov; 2021 Dec; 11(12):3198-3213. PubMed ID: 34301789
[TBL] [Abstract][Full Text] [Related]
12. Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells.
Ghasemi R; Struthers H; Wilson ER; Spencer DH
Leukemia; 2021 Feb; 35(2):404-416. PubMed ID: 32398790
[TBL] [Abstract][Full Text] [Related]
13. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract][Full Text] [Related]
14. Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice.
Muranyi A; Ammer T; Kechter A; Rawat VPS; Sinha A; Gonzalez-Menendez I; Quintanilla-Martinez L; Azoitei A; Günes C; Mupo A; Vassiliou G; Bamezai S; Buske C
Blood Adv; 2023 Feb; 7(3):351-364. PubMed ID: 35468619
[TBL] [Abstract][Full Text] [Related]
15. Targeting the undruggable: menin inhibitors ante portas.
Dempke WCM; Desole M; Chiusolo P; Sica S; Schmidt-Hieber M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9451-9459. PubMed ID: 37103568
[TBL] [Abstract][Full Text] [Related]
16. NPM1c impedes CTCF functions through cytoplasmic mislocalization in acute myeloid leukemia.
Wang AJ; Han Y; Jia N; Chen P; Minden MD
Leukemia; 2020 May; 34(5):1278-1290. PubMed ID: 31831844
[TBL] [Abstract][Full Text] [Related]
17. Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology.
Vascotto C; Lirussi L; Poletto M; Tiribelli M; Damiani D; Fabbro D; Damante G; Demple B; Colombo E; Tell G
Oncogene; 2014 May; 33(22):2876-87. PubMed ID: 23831574
[TBL] [Abstract][Full Text] [Related]
18. NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions.
Falini B
Am J Hematol; 2023 Sep; 98(9):1452-1464. PubMed ID: 37317978
[TBL] [Abstract][Full Text] [Related]
19. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
Heikamp EB; Henrich JA; Perner F; Wong EM; Hatton C; Wen Y; Barwe SP; Gopalakrishnapillai A; Xu H; Uckelmann HJ; Takao S; Kazansky Y; Pikman Y; McGeehan GM; Kolb EA; Kentsis A; Armstrong SA
Blood; 2022 Feb; 139(6):894-906. PubMed ID: 34582559
[TBL] [Abstract][Full Text] [Related]
20. NPM1-Mutated Acute Myeloid Leukemia: Recent Developments and Open Questions.
Patel SS
Pathobiology; 2024; 91(1):18-29. PubMed ID: 36944324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
